Neurocrine Stock Falls On Unusually High Volume (NBIX)

NEW YORK ( TheStreet) -- Neurocrine Biosciences (Nasdaq: NBIX) is trading at unusually high volume Tuesday with 1.5 million shares changing hands. It is currently at 4.1 times its average daily volume and trading down 83 cents (-9.2%) at $8.16 as of 10:40 a.m. ET.

Neurocrine has a market cap of $447.6 million and is part of the health care sector and drugs industry. Shares are up 5.8% year to date as of the close of trading on Monday.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company has a P/E ratio of 13.4, above the average drugs industry P/E ratio of 11.6 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Neurocrine as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, poor profit margins and feeble growth in the company's earnings per share. You can view the full Neurocrine Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Interested in other stocks that are falling on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVDOWN to 95370 or select from multiple alert options.
null